Literature DB >> 2935338

Suboptimal C3b/C3bi deposition and defective yeast opsonization. I. Evidence for the absence of essential co-factor activity.

M W Turner, N D Seymour, M D Kazatchkine, J F Mowbray.   

Abstract

Defective yeast opsonization in sera with no demonstrable abnormality of known complement components is associated with the absence of inactivity of a co-factor which enhances the deposition of C3 fragments (C3b/C3bi) derived from both classical and alternative pathways of complement activation. The factor binds strongly to zymosan at 4 degrees C and loses its biological activity completely when heated for 30 min at 56 degrees C but not when similarly heated at 50 degrees C. Sera with defective deposition of C3 fragments may be readily corrected with small quantities of sera having normal function. Sera with the defect do not correct other similar sera.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2935338      PMCID: PMC1577430     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  QUANTITATIVE DETERMINATION OF SERUM IMMUNOGLOBULINS IN ANTIBODY-AGAR PLATES.

Authors:  J L FAHEY; E M MCKELVEY
Journal:  J Immunol       Date:  1965-01       Impact factor: 5.422

2.  A rapid objective method for measuring the yeast opsonisation activity of serum.

Authors:  R J Levinsky; B A Harvey; S Paleja
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

3.  A defect of the alternative pathway of complement.

Authors:  J F Soothill; B A Harvey
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

4.  A simple automated method for complement estimation in a continuous flow system.

Authors:  U E Nydegger; L M Achermann; P H Lambert; P A Miescher
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

5.  The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway.

Authors:  H A Schenkein; S Ruddy
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

6.  IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b.

Authors:  F D Moore; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

7.  Defective opsonization. A common immunity deficiency.

Authors:  J F Soothill; B A Harvey
Journal:  Arch Dis Child       Date:  1976-02       Impact factor: 3.791

8.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

9.  The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan.

Authors:  H A Schenkein; S Ruddy
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

10.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

View more
  9 in total

1.  Deficiency of mannan binding protein--a new complement deficiency syndrome.

Authors:  M W Turner
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

2.  The level of mannan-binding protein regulates the binding of complement-derived opsonins to mannan and zymosan at low serum concentrations.

Authors:  M Super; R J Levinsky; M W Turner
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

3.  The role of opsonins in vacuolar sealing and the ingestion of zymosan by human neutrophils.

Authors:  A S Kemp; M W Turner
Journal:  Immunology       Date:  1986-09       Impact factor: 7.397

4.  Suboptimal C3b/C3bi deposition and defective yeast opsonization. II. Partial purification and preliminary characterization of an opsonic co-factor able to correct sera with the defect.

Authors:  M W Turner; N D Seymour; M D Kazatchkine; J F Mowbray
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

5.  Evaluation of C3b/C3bi opsonization and chemiluminescence with selected yeasts and bacteria using sera of different opsonic potential.

Authors:  M W Turner; C Grant; N D Seymour; B Harvey; R J Levinsky
Journal:  Immunology       Date:  1986-05       Impact factor: 7.397

6.  Mannose-binding lectin 2 (MBL2) gene polymorphism in asthma and atopy among adults.

Authors:  J Aittoniemi; H Soranummi; A T Rovio; M Hurme; T Pessi; M Nieminen; J Karjalainen
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

7.  New microbial and host factors in disseminated gonococcal infection: case report.

Authors:  G E Forster; A J Pinching; C A Ison; C S Easmon; P E Munday
Journal:  Genitourin Med       Date:  1987-06

Review 8.  Mammalian lectins in activation and clearance mechanisms involving the complement system.

Authors:  K B Reid; M W Turner
Journal:  Springer Semin Immunopathol       Date:  1994

Review 9.  Mannose-binding lectin in innate immunity: past, present and future.

Authors:  R M Dommett; N Klein; M W Turner
Journal:  Tissue Antigens       Date:  2006-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.